NCT02662569: A reported trial by Amgen
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02662569 |
|---|---|
| Title | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia (BERSON) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | April 14, 2016 |
| Completion date | Dec. 6, 2017 |
| Required reporting date | Dec. 6, 2018, midnight |
| Actual reporting date | Nov. 30, 2018 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |